Mark Exley

Company: Imvax

Job title: Chief Scientific Officer

Seminars:

GoldspireTM Personalized Tumour-Derived Late Stage Clinical Immunotherapy Platform Uses the Full Antigenic Signature of Solid Tumour to Induce Durable Anti-Tumour Immunity 4:50 pm

Goldspire personalized tumour-derived immunotherapy is safe and clinically active in glioblastoma Goldspire is active in multiple solid tumour preclinically, induces durable systemic anti-tumour immunity Goldspire is currently in late stage clinical development in glioblastomaRead more

day: Day One

Panel Discussion: Evaluating Different Combination Strategies to Develop More Effective Cancer Treatments for Curing the Patients in Need 2:30 pm

Which of the current state of the art immunotherapies are likely to combine well with neoantigen therapies? Beyond checkpoint inhibitors, what combinations seem the most promising? Are there certain combinations which work better for different stages of cancer? Discussing combining neoantigen therapies with PD-L1 therapies, chemotherapies and immunoglobins.Read more

day: Day Two